Cerebrohepatorenal syndrome and Epilepsy aggravated
Epilepsy aggravated is reported only by a few people with Cerebrohepatorenal syndrome.
The study analyzes which people have Epilepsy aggravated with Cerebrohepatorenal syndrome. It is created by eHealthMe based on 2 people who have Epilepsy aggravated and Cerebrohepatorenal syndrome from the Food and Drug Administration (FDA), and is updated regularly.
Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.
2 people who have Cerebrohepatorenal Syndrome and Epilepsy Aggravated are studied.
What is Cerebrohepatorenal syndrome?
Cerebrohepatorenal syndrome (absence of functional organelles in brain cells (by birth disorder )) is found to be associated with 6 drugs and 1 condition by eHealthMe.
What is Epilepsy aggravated?
Epilepsy aggravated (serious common and diverse set of chronic neurological disorders characterized by seizures) is found to be associated with 1,081 drugs and 371 conditions by eHealthMe.
Number of Epilepsy aggravated in Cerebrohepatorenal syndrome reports submitted per year:
Gender of people who have Cerebrohepatorenal Syndrome and experienced Epilepsy Aggravated *:
- female: 100 %
- male: 0.0 %
Age of people who have Cerebrohepatorenal Syndrome and experienced Epilepsy Aggravated *:
- 0-1: 50 %
- 2-9: 50 %
- 10-19: 0.0 %
- 20-29: 0.0 %
- 30-39: 0.0 %
- 40-49: 0.0 %
- 50-59: 0.0 %
- 60+: 0.0 %
Common co-existing conditions for these people *:
- Blood Bilirubin Increased: 1 person, 50.00%
Common drugs taken by these people *:
- Pyridoxine: 1 person, 50.00%
- Cholbam: 1 person, 50.00%
Common symptoms for these people *:
- White Blood Cell Count Increased: 1 person, 50.00%
- Weakness: 1 person, 50.00%
- Ammonia Increased: 1 person, 50.00%
- Anaemia (lack of blood): 1 person, 50.00%
- Apnea (temporary absence or cessation of breathing): 1 person, 50.00%
- Bronchiolitis (inflammation of the membranes lining the bronchioles in lungs): 1 person, 50.00%
- Conjunctivitis Viral (infection of conjunctiva by virus): 1 person, 50.00%
- Disease Progression: 1 person, 50.00%
- Enterovirus Infection: 1 person, 50.00%
- Gastric Haemorrhage (bleeding stomach): 1 person, 50.00%
* Approximation only. Some reports may have incomplete information.
Do you take medications and have Epilepsy aggravated?Check whether Epilepsy aggravated is associated with a drug or a condition
How to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
Treatments, associated drugs and conditions:
- Cerebrohepatorenal syndrome (99 reports)
- Epilepsy aggravated (695 reports)
COVID vaccines that are related to Epilepsy aggravated:
- Epilepsy aggravated in Moderna COVID Vaccine
- Epilepsy aggravated in Pfizer BioNTech Covid Vaccine
- Epilepsy aggravated in Johnson and Johnson Covid Vaccine
Common drugs associated with Epilepsy aggravated:
- Levetiracetam: 2,063 reports
- Keppra: 1,825 reports
- Tegretol: 1,418 reports
- Lamotrigine: 1,415 reports
- Lamictal: 1,286 reports
- Carbamazepine: 1,053 reports
- Depakene: 847 reports
- Valproate sodium: 770 reports
- Clonazepam: 693 reports
- Humira: 663 reports
All the drugs that are associated with Epilepsy aggravated:
- Epilepsy aggravated (1,081 drugs)
Common conditions associated with Epilepsy aggravated:
- Epilepsy: 3,186 reports
- Multiple sclerosis: 1,749 reports
- Depression: 1,073 reports
- High blood pressure: 840 reports
- Rheumatoid arthritis: 598 reports
- Pain: 533 reports
- Seizures: 532 reports
All the conditions that are associated with Epilepsy aggravated:
- Epilepsy aggravated (371 conditions)
How the study uses the data?
The study is based on Epilepsy aggravated and Cerebrohepatorenal syndrome, and their synonyms.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Zolmitriptan and Neutrophil Count Increased - 3 seconds ago
- Catapres and Acute Pulmonary Histoplasmosis - 6 seconds ago
- Spironolactone W/ Hydrochlorothiazide vs. Microzide - 14 seconds ago
- Valsartan and Tibia Fracture - 18 seconds ago
- Immunodeficiency Disorders and Atherosclerosis - 19 seconds ago
- Dovonex and Pramine drug interaction - 27 seconds ago
- Lyrica and Liver Transplant Rejection - 33 seconds ago
- Flonase and Ciprofloxacin drug interaction - 41 seconds ago
- Nadolol and Thiamine drug interaction - 43 seconds ago
- Prednisolone Acetate and Pseudoephedrine Hydrochloride drug interaction - 49 seconds ago